Breaking News Instant updates and real-time market news.

BAC

Bank of America

$25.87

0.42 (1.65%)

, WFC

Wells Fargo

$53.55

-1.66 (-3.01%)

12:36
10/13/17
10/13
12:36
10/13/17
12:36

On The Fly: Top stock stories at midday

Stocks opened with modest gains and have remained in positive territory throughout the morning. The high University of Michigan consumer confidence reading and more tepid than feared consumer inflation data helped hold the market in positive territory, as did a good quarterly report from Bank of America (BAC). ECONOMIC EVENTS: In the U.S., the preliminary University of Michigan survey for October showed consumer sentiment surged 6.0 points to a 13-year high reading of 101.1. business inventories rose 0.7% in August, with sales up 0.7% as well, as forecast. Retail sales surged in September, as expected, with a 1.6% headline rise and a 1.0% ex-auto gain both coming in a little stronger than forecast. The Consumer Prices Index rose 0.5%, with the core rate up 0.1% in September, which was not as hot as feared. COMPANY NEWS: Shares of Bank of America have advanced nearly 2% after the lender's headline earnings topped expectations and it noted that its revenue across its four lines of business grew 4%. Conversely, Wells Fargo (WFC) is down 3% after its earnings missed expectations due to accruals for legal charges related to its pre-crisis mortgage-related regulatory investigations. Wells Fargo, which has been dealing with fallout from its fake account scandal, also saw its revenue fall short of the consensus estimate... Insurers and hospital operators have been pressured after President Trump announced plans to cut off subsidy payments to insurers selling Affordable Care Act Coverage, a decision which leaked out after he signed an executive order pushing for new regulations to support cheap, loosely regulated health plans. Centene (CNC) has been among the hardest hit on the news, though Morgan Stanley analyst Zack Sopcak said he views today's weakness in Centene is particularly "exaggerated" and presents a buying opportunity. MAJOR MOVERS: Among the noteworthy gainers was Spartan Motors (SPAR), which rallied 13% after Craig-Hallum analyst Steven Dyer raised his price target on the shares to $20 from $13, saying the company's "ambitious" 2020 targets imply a 13% annual revenue growth and more than a tripling of earnings. Also higher was HP Inc. (HPQ), which gained 7% after the company provided better-than-expected adjusted earnings per share guidance for fiscal 2018. Among the notable losers was Antares Pharma (ATRS), which plunged 37% after it said that that the FDA has identified deficiencies that preclude the continuation of the discussion of labeling and postmarketing requirements/commitments of XYOSTED for testosterone replacement therapy. Also lower was Applied Optoelectronics (AAOI), which fell 19% after reporting third quarter preliminary results that fell short of estimates. INDEXES: Near midday, the Dow was up 41.48, or 0.18%, to 22,882.49, the Nasdaq was up 22.78, or 0.35%, to 6,614.29, and the S&P 500 was up 5.39, or 0.21%, to 2,556.32.

BAC

Bank of America

$25.87

0.42 (1.65%)

WFC

Wells Fargo

$53.55

-1.66 (-3.01%)

CNC

Centene

$89.61

-4.07 (-4.34%)

MOH

Molina Healthcare

$61.24

-2.18 (-3.44%)

UNH

UnitedHealth

$192.45

-0.47 (-0.24%)

WCG

WellCare

$169.06

0.75 (0.45%)

CI

Cigna

$186.01

-0.95 (-0.51%)

ANTM

Anthem

$185.50

-4.24 (-2.23%)

HNT

Health Net

HUM

Humana

$238.03

-3.41 (-1.41%)

AET

Aetna

$153.15

-1.34 (-0.87%)

SPAR

Spartan Motors

$14.70

2.55 (20.99%)

HPQ

HP Inc.

$21.89

1.49 (7.30%)

ATRS

Antares Pharma

$3.73

-0.21 (-5.33%)

AAOI

Applied Optoelectronics

$58.84

-2.6 (-4.23%)

  • 13

    Oct

  • 13

    Oct

  • 13

    Oct

  • 17

    Oct

  • 20

    Oct

  • 22

    Oct

  • 24

    Oct

  • 25

    Oct

  • 31

    Oct

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 07

    Nov

  • 08

    Nov

  • 16

    Nov

  • 29

    Nov

  • 15

    Jan

BAC Bank of America
$25.87

0.42 (1.65%)

08/09/17
WELS
08/09/17
INITIATION
WELS
Outperform
Bank of America resumed with an Outperform at Wells Fargo
Wells Fargo analyst Mike Mayo resumed coverage of Bank of America with an Outperform rating and $30 price target.
06/09/17
RBCM
06/09/17
NO CHANGE
RBCM
House financial reform bill unlikely to advance in Senate, says RBC Capital
RBC Capital analyst Gerard Cassidy says that the financial regulation reform bill passed yesterday by the House would help the banking sector but probably won;t be passed by the Senate. Large publicly traded banks include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).
07/11/17
BARD
07/11/17
NO CHANGE
BARD
Big bank set-up not great, would sell into extended rally, says Baird
Baird analyst David George does not see a great set-up for money-center banks heading into Q2 earnings. He said the trade looks crowded and he would be a seller into an extended rally. George said the risk/reward is less attractive following the sector's most recent rally as economic growth remains muted and the pace of NIM expansion may slow. George believes the biggest potential catalyst would be a gradual steepening of the yield curve and pick-up on loan growth.
07/18/17
NOMU
07/18/17
NO CHANGE
Target $27
NOMU
Buy
Bank of America NII softness could weight on shares, says Nomura Instinet
Nomura Instinet analyst Steven Chubak said Bank of America reported a modest core beat but the NII miss and elevated bar for Q3 could result in modest share underperformance. The analyst remains encouraged by fee income resiliency, favorable credit trends, strong capital build, and compelling risk/reward, and reiterates his Buy rating and $27 price target.
WFC Wells Fargo
$53.55

-1.66 (-3.01%)

09/26/17
DBAB
09/26/17
DOWNGRADE
Target $136
DBAB
Hold
PNC Financial downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Matt O'Connor downgraded PNC Financial (PNC) to Hold as he seeks to lessen exposure to traditional banks. The analyst sees net interest income growth slowing and credit costs inching up as the Fed raises short rates and the yield curve flattens. He believes a number of positives are priced into PNC shares. O'Connor upped his price target for the stock to $136 from $130. The analyst continues to prefer banks with a "turnaround angle," like Goldman Sachs (GS) and Wells Fargo (WFC), and remains positive on capital markets businesses like Morgan Stanley (MS). O'Connor this morning also downgraded JPMorgan (JPM) to Hold.
10/06/17
VERF
10/06/17
INITIATION
VERF
Sell
Wells Fargo initiated with a Sell at Vertical Group
Vertical Group analyst Richard Bove initiated earlier shares of Wells Fargo with a Sell rating and $49.67 price target.
09/28/17
NOMU
09/28/17
DOWNGRADE
NOMU
Neutral
U.S. Bancorp downgraded to Neutral from Buy at Nomura Instinet
Nomura Instinet analyst Bill Carcache downgraded U.S. Bancorp (USB) to Neutral saying he sees downside risk to net interest income and provision expectations. Consensus expects U.S. Bancorp's loan growth to accelerate to 6% by 2018, which is too optimistic given the bank's recent comments, the analyst contends. He lowered his price target for the shares to $55 from $57. Carcache remains bullish on Wells Fargo (WFC) and raised his price target for the shares to $65 from $64.
09/15/17
UBSW
09/15/17
NO CHANGE
Target $56
UBSW
Neutral
Wells Fargo revenue headwinds can persist, says UBS
UBS analyst Saul Martinez said proprietary analysis suggests Wells Fargo's difficult backdrop for client acquisition remains and the recent disclosures have kept the company in the spotlight for the wrong reasons. He believes earnings growth depends on efficiency improvement and more aggressive stock buybacks. Martinez maintained his Neutral rating and lowered his price target to $56 from $59 on Wells Fargo shares.
CNC Centene
$89.61

-4.07 (-4.34%)

10/02/17
BERN
10/02/17
NO CHANGE
BERN
Bernstein does not anticipate ACA fix/repeal before 2018 election
While noting the resignation of Health Secretary Tom Price, Bernstein analyst Lance Wilkes says he does not anticipate an Affordable Care act fix or ACA repeal before the 2018 election. The analyst expects tax reform will "suck the oxygen out of the room" until close to the election. A fix for 2019 is possible, but faces the headwind of the 2018 election campaign, he contends, adding that he believes CSR funding could be included in a trade for the upcoming budget and the Health Insurance Fee could be suspended as part of tax reform, but both are not highly likely at this point. Publicly traded companies in the space include Aetna (AET), Anthem (ANTM), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
10/13/17
10/13/17
NO CHANGE
Target $103

Overweight
Morgan Stanley sees Centene pullback on Trump ACA order as buying opportunity
As previously reported, Morgan Stanley analyst Zack Sopcak said he views today's weakness in Centene shares following President Trump's executive order to cut off ACA subsidy payments as a buying opportunity, highlighting three reasons that the move lower is particularly "exaggerated." First, New York AG Eric Schneiderman has said his state and a coalition of other, including California, plan to sue if subsidies were cut off, so the legal fight may delay the impact. Second, Centene has previously said it submitted two bids in most markets; one assuming Cost Sharing Reduction, or CSR, payments, one without. Third, following its pending Fidelis acquisition, he estimates total Centene exposure to exchanges to be about 8%, with roughly 60% of those receiving CSRs. Sopcak reiterate his Overweight rating and $103 price target on Centene, which is down 6% to $88 per share near midday.
10/13/17
MSCO
10/13/17
NO CHANGE
MSCO
Centene weakness a buying opportunity, says Morgan Stanley
10/13/17
LEER
10/13/17
NO CHANGE
LEER
Ending of ACA subsidies most negative for Centene, says Leerink
Leerink analyst Ana Gupte says the shutting off of the cost sharing subsidies on Affordable Care Act exchanges is most negative for Centene (CNC). The company is "highly profitable" on the exchanges at 15% of earnings, Gupte tells investors in a research note. Molina Healthcare (MOH) and Anthem (ANTM) are exposed on the top line but are losing money, the analyst adds. She notes that UnitedHealth (UNH), Humana (HUM) and Aetna (AET) have exited the exchanges while WellCare (WCG) has not been on them. Centene in premarket trading is down 6% to $88.00 while Molina is down 3% to $61.50.
MOH Molina Healthcare
$61.24

-2.18 (-3.44%)

09/21/17
MUFG
09/21/17
INITIATION
Target $70
MUFG
Neutral
Molina Healthcare initiated with a Neutral at MUFG
MUFG analyst Jason Twizell started Molina Healthcare with a Neutral rating and $70 price target.
10/12/17
MSCO
10/12/17
NO CHANGE
Target $68
MSCO
Overweight
Morgan Stanley says Molina CEO pick brings valuable experience
Joseph Zubretsky brings valuable MCO experience to his post as the new CEO of Molina Healthcare (MOH), said Morgan Stanley analyst Zack Sopcak, who added that he would be a buyer on weakness in the shares given that he expects earnings power to be unlocked over the next 12-18 months. During Zubretsky's tenure as CEO of Hanover Insurance (THG), the company's stock rose nearly 20%, while Aetna (AET) shares were up about 4% during his 6 years as CFO there, noted Sopcak, who keeps an Overweight rating on Molina.
UNH UnitedHealth
$192.45

-0.47 (-0.24%)

10/06/17
LEER
10/06/17
NO CHANGE
LEER
Leerink convinced Amazon entering drug distribution within two years
After calls with pharmacy benefit managers and retail pharmacy specialists, Leerink analyst Ana Gupte says she's convinced that Amazon.com (AMZN) "will almost certainly" enter the drug distribution value chain within two years, evolving into a more disruptive offering over time. Amazon's move is most threatening for retail pharmacies Walgreens Boots Alliance (WAB), CVS Health (CVS) and Wal-Mart (WMT), Gupte tells investors in a research note. The analyst calls Amazon both an opportunity and threat for Express Scripts (ESRX) and views UnitedHealth (UNH) and Humana (HUM) as "largely buffered." Gupte's conversations with specialists indicate Amazon is hiring relevant talent and is in active discussions with mid-market pharmacy benefit managers and possibly even with large players such as Prime Therapeutics. It is believed Amazon will start by capturing share in both the cash paying and third party mail order and possibly specialty pharmacy segments, Gupte notes. She expects Anthem (ANTM), Aetna (AET) and Cigna (CI) will likely to contemplate Amazon's entry in their upcoming PBM contract decisions.
08/30/17
ADAM
08/30/17
DOWNGRADE
Target $54
ADAM
Hold
The Advisory Board downgraded to Hold from Buy at Canaccord
Canaccord analyst Richard Close downgraded The Advisory Board (ABCO) to Hold from Buy based on the announced transaction to split the company by selling the Healthcare business to UnitedHealth's (UNH) Optum unit and the Education Business to Vista Equity Partners. Close lowered his price target to $54.29 on Advisory Board shares.
WCG WellCare
$169.06

0.75 (0.45%)

09/21/17
MUFG
09/21/17
INITIATION
Target $204
MUFG
Overweight
WellCare initiated with an Overweight at MUFG
MUFG analyst Jason Twizell started WellCare Health Plans with an Overweight rating and $204 price target.
10/09/17
COWN
10/09/17
INITIATION
Target $200
COWN
Outperform
WellCare initiated with an Outperform at Cowen
Cowen analyst Christine Arnold started WellCare Health Plans with an Outperform rating and $200 price target. The turnaround of the company's Medicare business has been "remarkably quick and successful," Arnold tells investors in a research note. The analyst believes organic enrollment growth and capital deployment will drive earnings growth.
CI Cigna
$186.01

-0.95 (-0.51%)

10/09/17
JPMS
10/09/17
DOWNGRADE
Target $253
JPMS
Neutral
Humana downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Gary Taylor downgraded Humana (HUM) to Neutral saying insider sales and the August board appointment render it unlikely that acquisition discussions are yet occurring. Further, the Republican's failed attempts to repeal and replace the Affordable Care Act have diminished the probability of the health industry fee repeal, which would have boosted Humana's earnings power by 20%, Taylor tells investors in a research note. The analyst still believes, however, a bid for Humana by Cigna (CI) is plausible in 2018. He keeps a $253 price target on the shares. Humana closed Friday up $1.59 to $246.90.
07/12/17
FBCO
07/12/17
INITIATION
Target $195
FBCO
Neutral
Anthem initiated with a Neutral at Credit Suisse
Credit Suisse analyst Scott Fidel started Anthem with a Neutral rating and $195 price target. The company has produced slower earnings growth over the past decade relative to Managed Care peers and its returns on capital are also "sub-par relative to comps," the analyst contends. He believes Anthem is "entering a new chapter" following the failed Cigna (CI) acquisition and "uncertain future" of the Affordable Care Act's exchanges and Medicaid expansion.
ANTM Anthem
$185.50

-4.24 (-2.23%)

09/19/17
RBCM
09/19/17
INITIATION
RBCM
Sector Perform
Express Scripts initiated with a Sector Perform at RBC Capital
RBC Capital analyst George Hill started coverage of Express Scripts (ESRX) with a $68 price target and a Sector Perform rating. The analyst says that the company "faces an uncertain future" in the wake of the loss of its deal with Anthem ( ANTM), as he believes that it will have difficulty generating operating profit growth without Anthem.
HNT Health Net

11/09/16
BERN
11/09/16
NO CHANGE
BERN
Health insurers to see multiple catalysts from Trump presidency, says Bernstein
Bernstein analyst Lance Wilkes says that "repealing and replacing Obamacare will be Trump's primary focus." The analyst expects health insurers to benefit from from the repeal of ACA taxes and the elimination of requirements to spend a certain percentage of revenue on medical costs. Wilkes expects Anthem (ANTM) and Blue Cross/Blue Shield providers to benefit from the elimination of public exchanges and broad coverage requirements. Other health insurers include Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
06/23/17
JEFF
06/23/17
NO CHANGE
JEFF
Jefferies says healthcare rally 'appropriate' after 'toothless' AHCA rewrite
Jefferies analyst David Windley said the rally yesterday in healthcare stocks was appropriate given the "anemic" rewrite of the AHCA healthcare bill by Senate Republicans. The key changes are removal of "pay-for" taxes, a somewhat longer runway for Exchange cost-sharing reduction subsidies, and delayed Medicaid transition to per capita caps, he tells investors. Windley called Cigna (CI) "probably the safest MCO in this noise", adding that Humana (HUM) would benefit most from the proposed removal of the health insurer fee. Other publicly traded healthcare insurers include Aetna (AET), Anthem (ANTM), Centene (CNC), Health Net (HNT), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
HUM Humana
$238.03

-3.41 (-1.41%)

10/09/17
10/09/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Humana (HUM) downgraded to Neutral from Overweight at JPMorgan with analyst Gary Taylor saying insider sales and the August board appointment render it unlikely that acquisition discussions are yet occurring. 2. Viacom (VIAB) downgraded to Sell from Neutral at Citi with analyst Jason Bazinet saying as media and cable companies jockey "for self-preservation," Charter Communications (CHTR) will likely drop, or significantly curtail, distribution of Viacom's content. 3. PTC Therapeutics (PTCT) downgraded to Underweight from Neutral at JPMorgan with analyst Anupam Rama saying the company's valuation remains at near pre-FDA Advisory Committee meetings levels, despite multiple "mixed / inconclusive / negative" updates recently. 4. Medtronic (MDT) downgraded to Market Perform from Outperform at Wells Fargo with analyst Larry Biegelsen saying a "lull" in major product cycles will drive below average organic sales growth over at least the next few quarters. 5. Symantec (SYMC) was downgraded to Underperform from Market Perform at Cowen and to Hold from Buy at Standpoint Research. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
AET Aetna
$153.15

-1.34 (-0.87%)

SPAR Spartan Motors
$14.70

2.55 (20.99%)

04/06/17
GHSC
04/06/17
INITIATION
Target $10
GHSC
Buy
Spartan Motors coverage assumed with a Buy at Seaport Global
Seaport Global analyst Rhem Wood assumed coverage on Spartan Motors with a Buy and a $10 price target saying it is still in the early stages of improving profitability and is wll positioned to take advantage of the growing ecommerce and final mile delivery markets.
01/25/17
ROTH
01/25/17
INITIATION
Target $12
ROTH
Buy
Spartan Motors initiated with a Buy at Roth Capital
Roth Capital analyst Matt Koranda started Spartan Motors with a Buy rating and $12 price target saying he believes its management team has initiated a "successful turnaround process," and sees upside in shares driven by "good" execution improving the emergency response segment.
10/13/17
CHLM
10/13/17
NO CHANGE
Target $20
CHLM
Buy
Spartan Motors price target raised to $20 from $13 at Craig-Hallum
Craig-Hallum analyst Steven Dyer raised his price target on Spartan Motors to $20 following the company's analyst day yesterday, saying its "ambitious" 2020 targets imply a 13% annual revenue growth and more than a tripling of earnings. Dyer says the recent USPS contract and operational improvements justify the higher price target given the management's "excellent" execution track record. The analyst kept his Buy rating on the stock.
HPQ HP Inc.
$21.89

1.49 (7.30%)

10/13/17
NEED
10/13/17
NO CHANGE
NEED
Needham views Stratasys, 3D Systems as vulnerable to HP expansion
Needham analyst James Ricchiuti believes HP Inc.'s (HPQ) plans to enter the metals 3D printing market in 2018, as announced at yesterday's analyst meeting, makes Stratasys (SSYS) and 3D Systems (DDD) potentially vulnerable to disruption. HP has placed multiple units of its Multi-Jet Fusion printers at leading customers in the automotive, consumer products, medical and electronics markets, which could hurt the core plastics and polymer printing businesses at Stratasys and 3D, Ricchiuti tells investors in a research note. He notes HP also plans to expand into the textiles printing market, which he finds not particularly surprising. The analyst is less concerned about the competitive challenge HP represents in this market to Electronics for Imaging (EFII) and Kornit Digital (KRNT). Electronics for Imaging's Nozomi platform appears to have an early lead and there is no evidence that HP is entering the direct-to-garment printing market, where Kornit has a "commanding position," Ricchiuti contends.
09/01/17
SBSH
09/01/17
NO CHANGE
Target $100
SBSH
Neutral
Tech Data price target lowered to $100 from $115 at Citi
Citi analyst Jim Suva explains why shares of Tech Data (TECD) dropped 20% on last night's disappointing earnings report. The cloud is gaining traction, allowing some vendors to shift products internally as well as less distributor rebates, which is resulting in increased competition and lower financial incentives, Suva tells investors in a post-earnings research note. He views Tech Data's earnings report as a negative for Sell-rated Arrow Electronics (ARW) and Avnet (AVT) as well as Neutral-rated Synnex (SNX), but a positive for HP Inc. (HPQ) and Apple (AAPL) as top line sales of PCs and smartphones are doing well. Suva cut his price target for Tech Data shares to $100 from $115 and keeps a Neutral rating on the name.
10/13/17
BERN
10/13/17
NO CHANGE
BERN
HP analyst day projected confident tone, says Bernstein
Bernstein analyst A.M. Sacconaghi says yesterday's FY18 guidance at HP Inc (HPQ) analyst day was better than expected, as management struck a "very confident tone". The analyst says there is opportunity for continue revenue growth and margin improvement in the PC business that is already "firing on all cylinders" and believes the FY18 outlook is "realistic to conservative." Sacconaghi also sees potential upside on EPS and FCF thanks to cost reduction and integration of Samsung's (SSNLF) printing business.
10/13/17
SBSH
10/13/17
NO CHANGE
SBSH
HP announcement to pressure 3D printing stocks, says Citi
HP (HPQ) at its analyst day announced two new 3D printing systems that will come to market in 2018, Citi analyst Kenneth Wong tells investors in a research note. Management suggested that the color printer will aim to significantly lower costs to drive accessibility and adoption, which could be viewed negatively for market incumbents, the analyst contends. He expects the news to pressure shares of 3D printing companies Stratasys (SSYS), 3D Systems (DDD) and voxeljet (VJET). Wong believes the early success of the Jet Fusion platform could cause customers to pause purchases to evaluate HP's new offerings.
ATRS Antares Pharma
$3.73

-0.21 (-5.33%)

06/23/17
HCWC
06/23/17
INITIATION
Target $5
HCWC
Buy
Antares Pharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis initiated Antares Pharma with a Buy and a $5 price target saying he sees further upside as its diversified business strategy finally matures in the near future. The analyst said Antares is a sum-of-the-parts story, and we believe several of those parts could come into clarity within months, including potential 3Q17 A/B-rated generic EpiPen approval, Antares' own Xyosted testosterone PDUFA date, Oct. 2017, partnered generic Byetta approval/launch, and partnered Makena auto injector Oct. 2017 PDUFA. Davis expects cash flow to breakeven in second half 2018, profitability in 2019, and said sum-of-the parts valuation results in a $5 price target.
10/13/17
HCWC
10/13/17
NO CHANGE
Target $5
HCWC
Buy
Antares worth $3.30 per share without Xyosted, says H.C. Wainwright
H.C. Wainwright analyst Oren Livnat says he's "at a loss" for what caused the FDA to send a letter to Antares Pharma over Xyosted deficiencies, well into labeling discussions and just nine days before the October 20 action date. However, with the stock indicating down over 40% to near $2 per share, the analyst highlights that his sum-of-the-parts valuation still yields $3.3 per share even if Xyosted is removed entirely from his model. Livnat keeps a Buy rating on Antares with a $5 price target.
04/20/17
RAJA
04/20/17
INITIATION
Target $4.3
RAJA
Strong Buy
Antares Pharma initiated with a Strong Buy at Raymond James
Raymond James analyst Elliot Wilbur initiated Antares Pharma with a Strong Buy and a $4.30 price target telling investors its business model diversity provides management with multiple value creation levers by playing in the generics arena targeting the $70B U.S. auto-injector and pre-filled syringe market, serving as life-cycle extension partner for branded assets facing end of life crisis or capturing full economic value of self-developed proprietary drugs.
05/10/17
JEFF
05/10/17
NO CHANGE
Target $6
JEFF
Buy
Jefferies sees Antares shares getting to $15 over time
Jefferies analyst Anthony Petrone views Antares Pharma's Q1 report as "solid" ahead of a "catalyst rich" second half of 2017. The better than expected results reflect continued strength in Sumatriptan device sales to Teva (TEVA) and a rebound in Otrexup, Petrone tells investors in a post-earnings research note. He believes four new products can win clearance in the second half of the year. Petrone sees the stock getting to $15 over time on successful launches from current pipeline products and keeps a Buy rating on Antares with a $6 price target. The stock in afternoon trading is down 4% to $2.67.
AAOI Applied Optoelectronics
$58.84

-2.6 (-4.23%)

10/13/17
COWN
10/13/17
NO CHANGE
Target $81
COWN
Outperform
Applied Optoelectronics price target lowered to $81 from $102 at Cowen
Cowen analyst Paul Silverstein lowered his price target on Applied Optoelectronics to $81 from $102 following the company's earnings pre-announcement. He said its announcement fuels concerns regarding the trajectory of its operating model, though he does not see an increased risk in the competitive landscape as his checks show they remain a strong supplier to a fast growing Web 2.0 data center end market. Silverstein maintained his Outperform rating on Applied Optoelectronics shares, which are down about 20% in pre-market trading to $47.25.
10/13/17
NEED
10/13/17
NO CHANGE
NEED
Applied Optoelectronics price target lowered to $75 from $115 at Needham
Needham analyst Alex Henderson cut his price target on Applied Optoelectronics (AAOI) after the company pre-announced lower than expected Q3 revenue. The analyst believes that the company's top customer, Amazon (AMZN), " completely stopped buying 40G" while Applied Optoelectronics lost share at Amazon. The analyst remains upbeat on the company's 100G business, however, and keeps a Strong Buy rating on the stock.
10/13/17
CHLM
10/13/17
DOWNGRADE
Target $42
CHLM
Hold
Applied Optoelectronics downgraded to Hold from Buy at Craig-Hallum
As previously reported, Craig-Hallum analyst Richard Shannon downgraded Applied Optoelectronics (AAOI) to Hold from Buy and cut his price target to $42 from $80 following a "substantial miss" in Q3. He says the 40G issues will continue to pressure the company and offset 100G growth in the near term, warning the company's gross margins could head much lower over next 1-2 quarters as it works through its inventory. Shannon also notes rising competition from Intel (INTC), as its aggressive pricing seeks to capture market share.
10/13/17
CHLM
10/13/17
DOWNGRADE
CHLM
Hold
Applied Optoelectronics downgraded to Hold from Buy at Craig-Hallum

TODAY'S FREE FLY STORIES

WAC

Walter Investment

$0.51

-0.0056 (-1.09%)

10:24
10/21/17
10/21
10:24
10/21/17
10:24
Hot Stocks
Walter Investment reaches agreement on financial restructuring »

Walter Investment has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMST

TimkenSteel

$17.57

0.19 (1.09%)

10:18
10/21/17
10/21
10:18
10/21/17
10:18
Hot Stocks
Tentative agreement between TimkenSteel, United Steelworkers voted down »

TimkenSteel employees who…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

AGEN

Agenus

$4.33

-0.14 (-3.13%)

, GSK

GlaxoSmithKline

$40.84

-0.26 (-0.63%)

10:15
10/21/17
10/21
10:15
10/21/17
10:15
Hot Stocks
FDA approves GlaxoSmithKline shingles vaccine with Agenus QS-21 Stimulon »

Agenus (AGEN) has…

AGEN

Agenus

$4.33

-0.14 (-3.13%)

GSK

GlaxoSmithKline

$40.84

-0.26 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 06

    Nov

MS

Morgan Stanley

$50.68

0.89 (1.79%)

10:06
10/21/17
10/21
10:06
10/21/17
10:06
Periodicals
Another 20% gain in Morgan Stanley stock likely, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

SSNLF

Samsung

10:02
10/21/17
10/21
10:02
10/21/17
10:02
Periodicals
Samsung has lots of upside driven by chips/screens, Barron's says »

Samsung stock is up 50%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 30

    Oct

DLAKY

Lufthansa

$30.28

0.2 (0.66%)

09:56
10/21/17
10/21
09:56
10/21/17
09:56
Periodicals
Lufthansa has more room to climb, Barron's says »

Amid competitor's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$59.90

0.12 (0.20%)

, DAL

Delta Air Lines

$53.27

1 (1.91%)

09:51
10/21/17
10/21
09:51
10/21/17
09:51
Periodicals
Market pounds United, sees American/Delta as possibly safe bets, Barron's says »

United Continental's…

UAL

United Continental

$59.90

0.12 (0.20%)

DAL

Delta Air Lines

$53.27

1 (1.91%)

AAL

American Airlines

$51.93

0.42 (0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 26

    Oct

  • 01

    Nov

CZR

Caesars

$12.20

0.15 (1.24%)

09:45
10/21/17
10/21
09:45
10/21/17
09:45
Periodicals
Caesars looks ready to grow again, Barron's says »

After a disastrous 2008…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 08

    Nov

DWDP

DowDuPont

$71.18

0.29 (0.41%)

09:40
10/21/17
10/21
09:40
10/21/17
09:40
Periodicals
DowDuPont shares likely to return as much as 30% over next year, Barron's says »

If DowDuPont can cut $3B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COH

Coach

$40.35

0.88 (2.23%)

09:29
10/21/17
10/21
09:29
10/21/17
09:29
Periodicals
Coach shares look undervalued, could rise nearly 30%, Barron's says »

Coach, which has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$96.50

1.8 (1.90%)

, MOH

Molina Healthcare

$64.40

0.76 (1.19%)

09:24
10/21/17
10/21
09:24
10/21/17
09:24
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

CNC

Centene

$96.50

1.8 (1.90%)

MOH

Molina Healthcare

$64.40

0.76 (1.19%)

CI

Cigna

$191.42

3.2 (1.70%)

ANTM

Anthem

$194.69

1.49 (0.77%)

AET

Aetna

$160.84

3.2 (2.03%)

HNT

Health Net

HUM

Humana

$245.81

3.12 (1.29%)

UNH

UnitedHealth

$207.49

4.24 (2.09%)

WCG

WellCare

$180.52

3.28 (1.85%)

CYH

Community Health

$6.44

0.24 (3.87%)

HCA

HCA Healthcare

$81.05

1.26 (1.58%)

LPNT

LifePoint

$58.35

0.5 (0.86%)

THC

Tenet

$14.66

1.31 (9.81%)

UHS

Universal Health

$112.85

2.31 (2.09%)

GOOG

Alphabet

$988.20

3.75 (0.38%)

GOOGL

Alphabet Class A

$1,005.07

3.23 (0.32%)

MSFT

Microsoft

$78.81

0.9 (1.16%)

FB

Facebook

$174.98

0.42 (0.24%)

INTC

Intel

$40.43

0.34 (0.85%)

IBM

IBM

$162.07

1.17 (0.73%)

MAR

Marriott

$115.02

-0.18 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 26

    Oct

  • 26

    Oct

  • 26

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 31

    Oct

  • 31

    Oct

  • 31

    Oct

  • 01

    Nov

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 02

    Nov

  • 02

    Nov

  • 03

    Nov

  • 06

    Nov

  • 08

    Nov

  • 08

    Nov

  • 08

    Nov

  • 15

    Nov

  • 15

    Nov

  • 29

    Nov

  • 30

    Nov

  • 18

    Mar

ETFC

E-Trade

$43.20

-0.49 (-1.12%)

08:55
10/21/17
10/21
08:55
10/21/17
08:55
Conference/Events
E-Trade to hold an education day »

Chicago Education Day is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

08:45
10/21/17
10/21
08:45
10/21/17
08:45
General news
Breaking General news story  »

New York Federal Reserve…

FB

Facebook

$174.98

0.42 (0.24%)

, AMZN

Amazon.com

$982.91

-3.7 (-0.38%)

08:25
10/21/17
10/21
08:25
10/21/17
08:25
Periodicals
Regulators inquiries fuel speculation about big tech breakup, Barron's says »

Facebook (FB), Amazon…

FB

Facebook

$174.98

0.42 (0.24%)

AMZN

Amazon.com

$982.91

-3.7 (-0.38%)

GOOG

Alphabet

$988.20

3.75 (0.38%)

GOOGL

Alphabet Class A

$1,005.07

3.23 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 26

    Oct

  • 26

    Oct

  • 01

    Nov

  • 08

    Nov

  • 15

    Nov

  • 29

    Nov

  • 18

    Mar

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

, AIMT

Aimmune

$25.66

-0.06 (-0.23%)

07:58
10/21/17
10/21
07:58
10/21/17
07:58
Hot Stocks
DBV believes FDA suggested continue moving forward with Viaskin »

DBV Technologies (DBVT)…

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

04:55
10/21/17
10/21
04:55
10/21/17
04:55
General news
Breaking General news story  »

New York Federal Reserve…

ETFC

E-Trade

$43.20

-0.49 (-1.12%)

04:55
10/21/17
10/21
04:55
10/21/17
04:55
Conference/Events
E-Trade to hold an education day »

Chicago Education Day is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

19:15
10/20/17
10/20
19:15
10/20/17
19:15
General news
Breaking General news story  »

Federal Reserve Chair…

ATRS

Antares Pharma

$2.18

0.06 (2.83%)

18:59
10/20/17
10/20
18:59
10/20/17
18:59
Hot Stocks
FDA cannot approve Antares Pharma's Xyosted NDA »

Antares Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

18:55
10/20/17
10/20
18:55
10/20/17
18:55
Conference/Events
Federal Reserve Chairperson delivers a lecture at NEC Dinner »

Federal Reserve…

SHIP

Seanergy Marine

$1.24

0.0199 (1.63%)

17:50
10/20/17
10/20
17:50
10/20/17
17:50
Syndicate
Breaking Syndicate news story on Seanergy Marine »

Seanergy Marine files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLI

Houlihan Lokey

$41.56

0.18 (0.43%)

17:49
10/20/17
10/20
17:49
10/20/17
17:49
Syndicate
Breaking Syndicate news story on Houlihan Lokey »

Houlihan Lokey files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

GEO

Geo Group

$26.20

0.2 (0.77%)

17:48
10/20/17
10/20
17:48
10/20/17
17:48
Syndicate
Breaking Syndicate news story on Geo Group »

Geo Group files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

, AIMT

Aimmune

$25.66

-0.06 (-0.23%)

17:37
10/20/17
10/20
17:37
10/20/17
17:37
Hot Stocks
DBV sinks following peanut allergy trial miss, Aimmune soars »

Shares of DBV…

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KALV

KalVista

$11.26

1.99 (21.47%)

, DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:24
10/20/17
10/20
17:24
10/20/17
17:24
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: KalVista (KALV),…

KALV

KalVista

$11.26

1.99 (21.47%)

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.